Evolva AG tick repellent

The Centers for Disease Control and Prevention (CDC) has published a Special Notice for the development and testing of a nootkatone-based body lotion with tick repellent and toxicant properties. The notice announces the CDC's intent to award a sole source firm fixed price contract to Evolva AG, a joint owner with the CDC on patents for the use of nootkatone to repel and kill arthropod pathogen vectors.

The purpose of the proposed contract is to continue services to refine and optimize the body lotion formulations with both repellent and toxicant activity against ticks. The period of performance is 18 months, from September 2024 to February 2026. Interested parties may identify their interest and capability to respond to the requirement or submit proposals, though the government will only negotiate with Evolva AG. All quotations or responses must be submitted by 12:00 PM EST on April 3, 2024. The statutory authority cited for the sole source award is 41 U.S.C. 3304, and a price and cost analysis, historical data, and comparison of rates with other large businesses were used to determine a fair and reasonable price.